Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Superberry showdown: aronia powder tested against COPD inflammation

NCT ID NCT06702696

Disease control Sponsor: Amasya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether eating freeze-dried aronia (black chokeberry) powder every day for 8 weeks can lower inflammation and improve breathing in people with COPD. Fifty participants aged 50-80 will be randomly assigned to take either the aronia powder or a placebo. Researchers will measure blood markers of inflammation and lung function before and after the trial.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
freeze-dried aronia (black chokeberry) powder
What this could lead to
If it works, this could point toward a natural dietary supplement to help manage inflammation and improve quality of life in COPD patients.
What could go wrong
This is a small, early-stage trial with only 50 participants. The results may not apply to everyone, and the supplement is not a replacement for standard COPD treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 50-80 years * Diagnosed with COPD * Not following a vegetarian or vegan diet * Willing to consume the provided aronia berry (black chokeberry) * Non-smokers * Have signed the informed consent form * Has not undergone endobronchial tube or valve surgery in the last two years. Exclusion Criteria: * Presence of associated chronic inflammatory/rheumatic diseases * Chronic infections that may create a prothrombotic state * Chronic kidney disease (CKD) * Malignancy * Hereditary thrombophilia * Essential thrombocythemia * Diagnosed endocrine disorders * Malabsorption disorders * Allergy to any food or berry fruits * Smoking * Participants who did not sign the informed consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yedikule Göğüs Hastalıkları Hastanesi

    RECRUITING

    Istanbul, Zeytinburnu, 34020, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.